William S. Sly

Last updated
William S. Sly
WSSly-Color.jpg
Born(1932-10-19)October 19, 1932
NationalityAmerican
Alma mater St. Louis University
Known for Sly Syndrome
SpouseMargaret Ann Sly
Children7
Awards National Academy of Sciences
Passano Foundation Award
Peter H. Raven Lifetime Achievement Award
Burlington Northern Foundation Faculty Achievement Award
Coriell Medal in Scientific Achievement
IBIS Marcel Simon Award
Scientific career
Fields Biochemistry
Institutions St. Louis University
Washington University in St. Louis

William S. Sly (born October 19, 1932) is an internationally known physician and scientist who, except for sabbatical years at Oxford and Stanford, spent his entire academic career in St. Louis. Following M.D. training at Saint Louis University School of Medicine, he trained in internal medicine at Washington University in St. Louis and in research laboratories at the NIH, in Paris, and in Madison, Wisconsin. He then joined the faculty at Washington University, where he directed the division of medical genetics for 20 years. In 1984, he was recruited to St. Louis University School of Medicine and appointed Alice A. Doisy Professor and chairman of the Edward A. Doisy Department of Biochemistry and Molecular Biology. He chaired that department for 26 years. In February 2007, he was also named the inaugural holder of the James B. and Joan C. Peters Endowed Chair in Biochemistry and Molecular Biology. He became an emeritus professor in July 2014.

Contents

Sly has made important contributions to several research areas. His group described the first patient with MPS VII (Sly syndrome) and worked with collaborators at The Jackson Laboratory to develop and characterize the mouse model of this disease. He headed studies that identified the mannose-6 phosphate and mannose receptors that target enzymes to lysosomes, which provided the rationale for enzyme replacement therapy in Gaucher’s disease and other lysosomal storage diseases. These discoveries led to his election to the National Academy of Sciences in 1989. He collaborated with the biotechnology company Ultragenyx to develop enzyme replacement for MPS VII (Sly Syndrome), which went into clinical trials in 2017. [1] The drug, Mepsevii, was approved by the FDA that same year. [2]

Sly also identified the first inherited deficiency of a human carbonic anhydrase, CA II, and defined the biochemical and molecular genetics of this disorder. His laboratory has since characterized many other carbonic anhydrases and produced mouse models of several CA deficiencies. With collaborators, he identified other human diseases attributed to mutations in the genes encoding CA IV, CA VA, and CA XII. Dr. Sly has also done research on hereditary hemochromatosis, collaborating on studies leading to the cloning of the HFE gene and identification of the product it encodes. He also showed that the HFE gene knockout in the mouse produces iron storage resembling human hemochromatosis.

Sly also contributed to resolution of a famous forensic case involving a “missing murder”. He and his colleague James Shoemaker provided evidence that a woman convicted for poisoning her child with ethylene glycol (antifreeze) and sentenced to life in prison without parole, was wrongly convicted. Instead, her child had the inherited disease methylmalonic acidemia. An abnormally elevated metabolite called propionic acid in the child’s serum had been misidentified as ethylene glycol. These findings led to her release and exoneration. [3] [4]

Sly has received many awards and honors for his research accomplishments, including induction into the National Academy of Sciences in 1989, the Coriell Medal from the Coriell Institute for Medical Research in Camden, New Jersey, for pioneering work in human genetics, the Peter H. Raven Lifetime Achievement Award from the Academy of Science of St. Louis, the Marcel Simon Prize from The Hemochromatosis Society in Albany, NY and the World Congress of Iron Metabolism in Cairns, Australia, the Distinguished Scientist Award from the Clinical Ligand Assay Society, the Passano Foundation Award (shared with Stuart Kornfeld), and the Burlington Northern Foundation Faculty Achievement Award for outstanding research. Dr. Sly has served on the Scientific Review Board and Medical Advisory Board for the Howard Hughes Medical Institute, the Board of Scientific Overseers for the Jackson Laboratory, and on many scientific societies and other foundations. He served on the editorial boards for several journals and was an editor for the classic metabolic text, The Metabolic and Molecular Bases of Inherited Diseases .

Sly received an honorary doctor of science degree from Washington University in St. Louis in 2007. WSSly-WUSTL-Color.jpg
Sly received an honorary doctor of science degree from Washington University in St. Louis in 2007.

Related Research Articles

<span class="mw-page-title-main">Sly syndrome</span> Medical condition

Sly syndrome, also called mucopolysaccharidosis type VII (MPS-VII), is an autosomal recessive lysosomal storage disease caused by a deficiency of the enzyme β-glucuronidase. This enzyme is responsible for breaking down large sugar molecules called glycosaminoglycans. The inability to break down GAGs leads to a buildup in many tissues and organs of the body. The severity of the disease can vary widely.

<span class="mw-page-title-main">Mucopolysaccharidosis</span> Medical condition

Mucopolysaccharidoses are a group of metabolic disorders caused by the absence or malfunctioning of lysosomal enzymes needed to break down molecules called glycosaminoglycans (GAGs). These long chains of sugar carbohydrates occur within the cells that help build bone, cartilage, tendons, corneas, skin and connective tissue. GAGs are also found in the fluids that lubricate joints.

β-Glucuronidase Class of enzymes

β-Glucuronidases are members of the glycosidase family of enzymes that catalyze breakdown of complex carbohydrates. Human β-glucuronidase is a type of glucuronidase that catalyzes hydrolysis of β-D-glucuronic acid residues from the non-reducing end of mucopolysaccharides such as heparan sulfate. Human β-glucuronidase is located in the lysosome. In the gut, brush border β-glucuronidase converts conjugated bilirubin to the unconjugated form for reabsorption. β-Glucuronidase is also present in breast milk, which contributes to neonatal jaundice. The protein is encoded by the GUSB gene in humans and by the uidA gene in bacteria.

<span class="mw-page-title-main">Renal tubular acidosis</span> Medical condition

Renal tubular acidosis (RTA) is a medical condition that involves an accumulation of acid in the body due to a failure of the kidneys to appropriately acidify the urine. In renal physiology, when blood is filtered by the kidney, the filtrate passes through the tubules of the nephron, allowing for exchange of salts, acid equivalents, and other solutes before it drains into the bladder as urine. The metabolic acidosis that results from RTA may be caused either by insufficient secretion of hydrogen ions into the latter portions of the nephron or by failure to reabsorb sufficient bicarbonate ions from the filtrate in the early portion of the nephron. Although a metabolic acidosis also occurs in those with chronic kidney disease, the term RTA is reserved for individuals with poor urinary acidification in otherwise well-functioning kidneys. Several different types of RTA exist, which all have different syndromes and different causes. RTA is usually an incidental finding based on routine blood draws that show abnormal results. Clinically, patients may present with vague symptoms such as dehydration, mental status changes, or delayed growth in adolescents.

<span class="mw-page-title-main">HFE (gene)</span> Mammalian protein found in Homo sapiens

Human homeostatic iron regulator protein, also known as the HFE protein, is a transmembrane protein that in humans is encoded by the HFE gene. The HFE gene is located on short arm of chromosome 6 at location 6p22.2

Inclusion-cell (I-cell) disease, also referred to as mucolipidosis II, is part of the lysosomal storage disease family and results from a defective phosphotransferase. This enzyme transfers phosphate to mannose residues on specific proteins. Mannose-6-phosphate serves as a marker for proteins to be targeted to lysosomes within the cell. Without this marker, proteins are instead secreted outside the cell, which is the default pathway for proteins moving through the Golgi apparatus. Lysosomes cannot function without these proteins, which function as catabolic enzymes for the normal breakdown of substances in various tissues throughout the body. As a result, a buildup of these substances occurs within lysosomes because they cannot be degraded, resulting in the characteristic I-cells, or "inclusion cells" seen microscopically. In addition, the defective lysosomal enzymes normally found only within lysosomes are instead found in high concentrations in the blood, but they remain inactive at blood pH because they require the low lysosomal pH 5 to function.

Iduronidase, sold as Aldurazyme, is an enzyme with the systematic name glycosaminoglycan α-L-iduronohydrolase. It catalyses the hydrolysis of unsulfated α-L-iduronosidic linkages in dermatan sulfate.

<span class="mw-page-title-main">Arylsulfatase B</span> Mammalian protein found in Homo sapiens

Arylsulfatase B is an enzyme associated with mucopolysaccharidosis VI.

In medical genetics, compound heterozygosity is the condition of having two or more heterogeneous recessive alleles at a particular locus that can cause genetic disease in a heterozygous state; that is, an organism is a compound heterozygote when it has two recessive alleles for the same gene, but with those two alleles being different from each other. Compound heterozygosity reflects the diversity of the mutation base for many autosomal recessive genetic disorders; mutations in most disease-causing genes have arisen many times. This means that many cases of disease arise in individuals who have two unrelated alleles, who technically are heterozygotes, but both the alleles are defective.

<span class="mw-page-title-main">Carbonic anhydrase II</span> Protein-coding gene in the species Homo sapiens

Carbonic anhydrase II, is one of sixteen forms of human α carbonic anhydrases. Carbonic anhydrase catalyzes reversible hydration of carbon dioxide. Defects in this enzyme are associated with osteopetrosis and renal tubular acidosis. Renal carbonic anhydrase allows the reabsorption of bicarbonate ions in the proximal tubule. Loss of carbonic anhydrase activity in bones impairs the ability of osteoclasts to promote bone resorption, leading to osteopetrosis.

<span class="mw-page-title-main">Carbonic anhydrase 9</span> Protein-coding gene in the species Homo sapiens

Carbonic anhydrase IX is an enzyme that in humans is encoded by the CA9 gene. It is one of the 14 carbonic anhydrase isoforms found in humans and is a transmembrane dimeric metalloenzyme with an extracellular active site that facilitates acid secretion in the gastrointestinal tract. CA IX is overexpressed in many types of cancer including clear cell renal cell carcinoma (RCC) as well as carcinomas of the cervix, breast and lung where it promotes tumor growth by enhancing tumor acidosis.

<span class="mw-page-title-main">CA1 (gene)</span> Protein-coding gene in the species Homo sapiens

Carbonic anhydrase 1 is an enzyme that in humans is encoded by the CA1 gene.

<span class="mw-page-title-main">Carbonic anhydrase 4</span> Protein-coding gene in the species Homo sapiens

Carbonic anhydrase 4 is an enzyme that in humans is encoded by the CA4 gene.

<span class="mw-page-title-main">Carbonic anhydrase 12</span> Protein-coding gene in the species Homo sapiens

Carbonic anhydrase 12 is an enzyme that in humans is encoded by the CA12 gene.

<span class="mw-page-title-main">Carbonic anhydrase VI</span> Protein-coding gene in the species Homo sapiens

Carbonic anhydrase 6 is an enzyme that in humans is encoded by the CA6 gene. It is also called 'gustin' because of its presence in saliva, and lower-than-normal levels of salivary zinc in individuals with hypogeusia.

<span class="mw-page-title-main">Carbonic anhydrase 7</span> Protein-coding gene in the species Homo sapiens

Carbonic anhydrase 7 (CA7) is an enzyme that in humans is encoded by the CA7 gene.

Haemochromatosis type 3 is a type of iron overload disorder associated with deficiencies in transferrin receptor 2. It exhibits an autosomal recessive inheritance pattern. The first confirmed case was diagnosed in 1865 by French doctor Trousseau. Later in 1889, the German doctor von Recklinghausen indicated that the liver contains iron, and due to bleeding being considered to be the cause, he called the pigment "Haemochromatosis." In 1935, English doctor Sheldon's groundbreaking book titled, Haemochromatosis, reviewed 311 patient case reports and presented the idea that haemochromatosis was a congenital metabolic disorder. Hereditary haemochromatosis is a congenital disorder which affects the regulation of iron metabolism thus causing increased gut absorption of iron and a gradual build-up of pathologic iron deposits in the liver and other internal organs, joint capsules and the skin. The iron overload could potentially cause serious disease from the age of 40–50 years. In the final stages of the disease, the major symptoms include liver cirrhosis, diabetes and bronze-colored skin. There are four types of hereditary hemochromatosis which are classified depending on the age of onset and other factors such as genetic cause and mode of inheritance.

Emil Kakkis is an American medical geneticist known for his work to develop treatments for ultra rare disorders. He is the Founder of the Everylife Foundation for Rare Disease and Founder, CEO and President of Ultragenyx Pharmaceutical Inc.

Vestronidase alfa, sold under brand name Mepsevii, is a drug for the treatment of Sly syndrome. It is a recombinant form of the human enzyme beta-glucuronidase. It was approved in the United States in November 2017, to treat children and adults with an inherited metabolic condition called mucopolysaccharidosis type VII, also known as Sly syndrome. MPS VII is an extremely rare, progressive condition that affects most tissues and organs.

<span class="mw-page-title-main">Ultragenyx</span>

Ultragenyx is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

References

  1. "MPS 7 for Patients | Lysosomal Storage Disorder | Metabolic | Rare Disease | Ultragenyx". www.ultragenyx.com. Retrieved 2017-01-29.
  2. "Ultragenyx Announces FDA Approval of MEPSEVII™ (vestronidase alfa), the First Therapy for Progressive and Debilitating Rare Genetic Disease Mucopolysaccharidosis VII". Ultragenyx.com. Retrieved 27 June 2021.
  3. "Patricia Stallings - National Registry of Exonerations". www.law.umich.edu. Retrieved 2017-01-29.
  4. "The Murder That Never Was – Vol. 36 No. 23". PEOPLE.com. 1991-12-16. Retrieved 2017-01-29.

Further reading